Study of INOpulse for Pulmonary Arterial Hypertension Reveals Positive Data
Bellerophon Therapeutics recently announced that INOpulse, a type of nitric oxide that helps blood vessels expand, is effective in treating Pulmonary Arterial Hypertension (PAH) based on middle-stage data from a Phase 2 trial. The US Food and Drug Administration (FDA) has issued a Special Protocol Assessment (SPA), which will help to…